As of June 2026, Docon held 9,69,69,696 shares, representing a 60.92% stake in Thyrocare. Following the sale of 1,57,69,696 shares, its shareholding declined to 51.02% of the company's paid-up equity. Docon continues to remain a promoter and holding company of Thyrocare.

The shares sold were part of Docon's holding in Thyrocare. Docon had earlier pledged its entire 9,69,69,696-share holding as security for non-convertible debentures issued by API Holdings, its parent company. Following the release of the 1.75 crore-share pledge, the encumbered portion stood at 7,94,69,696 shares, or 49.93% of Thyrocare's total share capital.

The outstanding principal amount of the NCDs issued by API Holdings stood at Rs 1,050 crore as of the date of the disclosure.

Thyrocare Technologies is a fully automated laboratory chain with a pan-India presence. The company reported a strong Q1 FY27, with consolidated revenue rising 24.3% YoY to Rs 240.02 crore and PAT increasing 34.1% YoY to Rs 51.33 crore.